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Stem cell therapies have had tremendous potential application for many diseases in
recent years. However, the tumorigenic properties of stem cells restrict their potential
clinical application; therefore, strategies for reducing the tumorigenic potential of stem
cells must be established prior to transplantation. We have demonstrated that syngeneic
transplantation of embryonic stem cells (ESCs) provokes an inflammatory response that
involves the rapid recruitment of bone marrow-derived macrophages (BMDMs). ESCs
are able to prevent mature macrophages from macrophage colony-stimulating factor (M-
CSF) withdrawal-induced apoptosis, and thus prolong macrophage lifespan significantly by
blocking various apoptotic pathways in an M-CSF-independent manner. ESCs express and
secrete IL-34, which may be responsible for ESC-promoted macrophage survival.This anti-
apoptotic effect of ESCs involves activation of extracellular signal-regulated kinase (ERK)1/2
and PI3K/Akt pathways and thus, inhibition of ERK1/2 and PI3K/AKT activation decreases
ESC-induced macrophage survival. Functionally, ESC-treated macrophages also showed
a higher level of phagocytic activity. ESCs further serve to polarize BMDMs into M2-like
macrophages that exhibit most tumor-associated macrophage phenotypic and functional
features. ESC-educated macrophages produce high levels of arginase-1, Tie-2, and TNF-
α, which participate in angiogenesis and contribute to teratoma progression. Our study
suggests that induction of M2-like macrophage activation is an important mechanism
for teratoma development. Strategies targeting macrophages to inhibit teratoma devel-
opment would increase the safety of ESC-based therapies, inasmuch as the depletion of
macrophages completely inhibits ESC-induced angiogenesis and teratoma development.
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INTRODUCTION
Stem cell-based therapies possess promising outcomes for many
conditions, including spinal cord injury and other neurologi-
cal degenerative disorders. However, this powerful therapeutic
strategy is problematic because the pluripotency of stem cells is
accompanied by a large risk of tumor formation after transplanta-
tion. Theoretically, three classes of tumors can be envisaged to arise
from pluripotent stem cells (PSCs) including embryonic stem cells
(ESCs) and induced pluripotent stem cells (iPSCs); viz. teratomas,
teratocarcinomas, and secondary tumors (1). Teratoma is con-
stituted by cells from endodermal, mesodermal, and ectodermal
lineages (2–4). Not only ESCs but also ESC-derived neuronal prog-
enitors can induce teratomas in animal models (5). The tumori-
genicity of stem cells is the major obstacle to the successful appli-
cation of stem cell-based therapies (6). The safety issue of stem
cells must be evaluated properly and the adverse consequences of
teratoma formation from these stem cells must be overcome before
stem cell therapy can be used for clinical application.
Various strategies developed to reduce this risk of teratoma
formation include prolonged pre-differentiation of ESCs in vitro,
blocking signaling pathways that promote proliferation, induction
of apoptosis of proliferative ESCs, sorting cells expressing precur-
sor markers, and deleting undifferentiated ESCs immunologically,
genetically, and chemically (7–18). However, it is difficult to obtain
a yield of 100% pure differentiated stem cells for transplanta-
tion: the contamination of grafts with undifferentiated cells can
give rise to teratoma formation (19–21). Furthermore, teratoma
could potentially develop into highly malignant teratocarcinoma,
which constitutes of persistent and undifferentiated stem cells
(22). Therefore, efforts must be made to ensure safe transplan-
tation of a PSC-based cell treatment. We used undifferentiated
ESCs as a worst-case model for teratoma formation by stem cells
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and studied the role of macrophages and niche microenvironment
of stem cell growth in the progression of teratomas.
The interplay of immune cells, especially macrophages and
ESCs, causes alterations in the microenvironment and poten-
tial for tumorigenicity, which regulate the initiation, progres-
sion, angiogenesis, and metastasis of tumor. Thus, targeting this
immune response can significantly inhibit the evolution of tumors
(23, 24). Our previous data also demonstrated that interaction
between transplanted ESCs and macrophages creates a microen-
vironment that facilitates the initiation and progression of ter-
atomas (24). Infiltrated macrophages deliver macrophage migra-
tion inhibitory factor (MIF) and other angiogenic factors to stimu-
late endothelial cell proliferation and pericyte differentiation (24).
There is growing evidence to suggest that macrophages promote
tumorigenesis and that the tumor microenvironment polarizes
macrophages toward an M2 (pro-tumor) phenotype, with prop-
erties that differ from the M1 phenotype (25–28). However, the
role of macrophages in ESC growth and teratoma development
is not clear. In this study, we demonstrate that ESCs promote
macrophage survival and M2-like activation are critically impor-
tant for teratoma angiogenesis and development. Significantly, we
show that depletion of macrophages inhibits teratoma growth
tremendously. Therefore, ESC-educated macrophages are con-
sidered attractive targets for an anti-teratoma strategy after ESC
transplantation.
MATERIALS AND METHODS
REAGENTS AND ANTIBODIES
All the chemicals were purchased from Sigma (St. Louis, MO, USA)
and cell culture media were purchased from Invitrogen (Carls-
bad, CA, USA) unless specifically noted. The F4/80 hybridoma
cell line was from American Tissue Culture Collection (ATCC,
Manassas, VA, USA). Recombinant mouse IL-34 was from R&D
Systems (Minneapolis, MN, USA). The primary antibodies used in
the study are listed in Table 1. All Alexa Fluor- or HRP-conjugated
secondary antibodies were from Invitrogen.
MICE
C57BL/6 mice and transgenic CX3CR1GFP mice from Jackson Lab-
oratory (Bar Harbor, ME, USA) were maintained in the pathogen-
free animal facility in Rutgers, the State University of New Jersey.
All animal experimental protocols were authorized by the Animal
Care and Facilities Committee of Rutgers, the State University of
New Jersey and Florida State University.
PREPARATION OF MOUSE BONE MARROW-DERIVED MACROPHAGES
Mouse bone marrow-derived macrophages (BMDMs) from
C57BL/6 mice were prepared as described (24). Briefly, BM cells
from mice 6–8 weeks of age were collected from femoral shafts
by flushing the marrow cavity of femurs with Dulbecco’s modi-
fied eagle medium (DMEM) supplemented with 1% fetal bovine
serum (FBS). The cell suspensions were passed through an 18-
gage needle to disperse cell clumps. Cells were cultured for 7 days
at a cell density of 1× 106/ml in 100 mm polystyrene tissue cul-
ture dishes (BD Biosciences) containing DMEM supplemented
with 15% conditioned medium from L929 cells [a source of
macrophage colony-stimulating factor (M-CSF)] and 10% FBS.
Table 1 | Antibodies included in the study.
Protein name Antibody ID Manufacturer
AKT 4685 Cell Signaling
Arginase-1 sc-18354 Santa Cruz
Caspase-9 9504 Cell Signaling
CD31 553708 BD Biosciences
CD45 103108 BioLegend
Cytochrome c 4272 Cell Signaling
ERK1/2 4695 Cell Signaling
GAPDH 2118 Cell Signaling
IBA-1 019-19741 Wako
IL-34 PAB13397 Abnova
M-CSF 3155 Cell Signaling
PI3K p85 4257 Cell Signaling
Iκbα (Ser32) 2859 Cell Signaling
Phospho-Akt 9271 Cell Signaling
Phospho-ERK1/2 4370 Cell Signaling
Phospho-PI3K p85 4228 Cell Signaling
Tie-2 sc-9026 Santa Cruz
YM1 01404 Stem Cell Technologies
Cell morphology was analyzed by image capture (Carl Zeiss,
Germany) and using LSM 510 software (Nikon, Japan). The long
axis, defined as the longest length of the cells, was manually traced
and measured.
ESC CULTURE AND PREPARATION OF ESC-CONDITIONED MEDIUM
The mouse green fluorescent protein (GFP)-expressing -ESC line
(F12) derived from C57BL/6 mouse was a kind gift from Professor
Melitta Schachner (Rutgers University). Freshly thawed ESCs (P0)
were seeded into a 10-cm tissue culture dish in the presence of
mitomycin-treated murine embryo fibroblast (MEF) feeder layer,
in ESC media [103 U/ml LIF (Millipore, CA, USA), 15% FBS, 1%
non-essential amino acids solution (MEM), 200 mM l-glutamine,
1% nucleoside solution, 1% 100 nM Na-Pyruvate, and 0.2% 2-
Mercaptoethanol in DMEM]. LIF was added every day into the
culture medium. After 3–4 passages, ESCs were maintained only
on a 0.1% gelatin-coated tissue culture dish without a feeder layer.
ESC colonies were sub-cultured for every 2–3 days and their super-
natant was collected as conditioned medium. ESC-conditioned
medium (ESC-CM) was prepared by spinning the ESCs at
1,000 rpm for 5 min to pellet the cells, while the supernatant was
again spun at 2,500 rpm for 10 min to remove any debris. Super-
natant was then filtered through a 0.4-µ filter (Corning, USA).
Supernatant collected from multiple passages was pooled together
and stored at −80°C. Regular culture medium without ESCs was
incubated in the same way and used as control medium (Con-M).
HISTOLOGY AND IMMUNOFLUORESCENCE
Mice were transcardially perfused with 0.9% saline followed by
4% paraformaldehyde. A segment of tissue encompassing the
transplantation site was removed and fixed in 4% paraformalde-
hyde for 3 h and then cryoprotected in 20% sucrose overnight at
4°C. For histologic examination, the sections were stained with
hematoxylin and eosin (H&E). For immunofluorescence staining,
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the sections were incubated with primary antibodies overnight at
room temperature (RT) followed by secondary antibodies at RT
for 2 h. Non-specific binding was excluded by using secondary
antibody only. Samples were examined and microphotographs
were taken using a Zeiss AxioCam microscope and an AxioPhot
image collection system (Carl Zeiss, Germany), and Confocal
Laser Scanning Microscopy (Nikon, Japan). Tumor volume was
determined as follows: short diameter2× long diameter× 1/2.
TRANSPLANTATION AND ESCs IN SPINAL CORD AND LIVER
Laminectomy was performed on WT and chimerical mice at the
T9–T10 level to expose the spinal cord. GFP–ESCs (50,000 in 1µl
DMEM) were injected slowly at this segment of each mouse’s
spinal cord using a microliter syringe (Hamilton Company, NV,
USA) fixed in a stereotaxic frame. ESCs (100,000 in 5.0µl DMEM)
were also injected slowly via microliter syringe into the left lobe
of mouse liver. Mice were sacrificed and perfused at different time
points after cell transplantation.
MTT ASSAY
To determine cell viability the colorimetric MTT metabolic activ-
ity assay was used. BMDMs were seeded in a 96-well plate at a
density of 8,000 cell per well and cells were treated with Con-
M and ESC-M for 48 h. MTT [3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide] was added to each well and plate
was incubated for 4 h. Finally, the absorbance was measured at
540 nm by using a microplate reader. The relative MTT uptake (%
cell viability) was expressed as a percentage relative to the control
cells.
PHAGOCYTIC FUNCTION TEST
Mature BMDMs were seeded in a 96-well culture plate at a den-
sity of 1× 104 cells/well and incubated with Con-M and ESC-M
for 24 h. BMDMs were incubated with carboxylate-modified flu-
orescent red Latex beads and apoptotic cells for 1 h, respectively.
Non-ingested particles were washed away and phagocytosis was
imaged by a Zeiss Axiovert 200 M Microscope (Carl Zeiss) and
software AxioVision 4.6 (Carl Zeiss).
ARGINASE ACTIVITY ASSAY
To prepare the cell lysate for assay of arginase activity, BMDMs
were rinsed with PBS after each specific treatment and 1× 105
BMDMs from each group were lysed in 100µl of lysis buffer con-
taining 10 mM Tris-HCl (pH 7.4), proteinase inhibitor cocktail,
and 0.4% Triton-X 100 for 10 min. Arginase activity of various cell
lysate was measured by quantitative colorimetric assay of arginase
activity (Bioassay Systems, CA, USA) according to the manufac-
turer’s instructions. One unit of arginase activity is defined as
1µmol of l-arginine converted to ornithine and urea per minute
at pH 9.5 and 37°C. Urea concentration, as the degree of arginase
activity, was measured at 520 nm at RT by spectrometer.
ANNEXIN V AND PROPIDIUM IODIDE STAINING
Bone marrow-derived macrophages were rinsed with PBS after
each specific treatment and the apoptosis of BMDMs was mea-
sured by PE Annexin V Apoptosis Detection Kit I (BD Biosciences,
CA, USA) according to the manufacturer’s instructions. Binding
of Annexin V and PI was measured by a flow cytometer (BD Bio-
sciences, CA, USA) and analyzed using FlowJo software (FlowJo,
NJ, USA).
RNA ISOLATION AND QUANTITATIVE REAL-TIME-PCR
Bone marrow-derived macrophages were incubated with Con-M
and ESC-M for 6 and 12 h, respectively. Total RNA was iso-
lated by TRIZOL and reverse-transcribed into cDNA by using
oligo-dT primers and SuperScript II Reverse Transcriptase. The
TNF-α primer pair (5′-ATGCTGGGACAGTGACCTGG-3′ and
5′-CCTTGATGGTGGTGCATGAG-3′) was specifically designed
for mRNA. The ABI7900HT detection system (Applied Biosys-
tems, UK) was used for quantitative real-time (qRT)-PCR. SYBR
Green dye (Applied Biosystems) was used to monitor the replica-
tion of PCR products. Quantification of products were obtained
by standard curve and then normalized to GAPDH amount.
The gene expression level was represented by the ratio of gene
TNF-α/GAPDH.
WESTERN BLOT
Western blot assay was performed following the standard pro-
cedure. Briefly, after washing with ice-cold PBS, cells were lysed
with RIPA buffer containing phosphatase inhibitor and proteinase
inhibitor cocktail. Total cellular proteins were loaded onto SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and then trans-
ferred to PVDF membranes (GE Healthcare, UK). After blocking
in 5% milk or BSA (according to antibody manufacturer’s instruc-
tions) in Tris-buffered saline containing 0.1% Tween 20 (TBST)
for 1 h at RT, membranes were incubated with appropriate pri-
mary antibody solution overnight at 4°C. Membranes were placed
in appropriate secondary antibody for 1 h after rinsing in TBST.
Subsequently, proteins were visualized by ECL plus western blot
detection system (GE Healthcare, UK).
EX VIVO MOUSE AORTIC RING ASSAY
Mouse aortic ring assay was carried out as described (29) using
C57BL/6 mice (8–12 weeks). Briefly, thoracic aortic segments were
cut into 1-mm rings and carefully placed with the lumen of the
rings opened up on Matrigel (BD Biosciences) with Con-M or
ESC-M and then overlaid with an additional Matrigel. Aortic
rings were examined daily and digital images were taken at day
6 for quantitative analysis of the area of vessel outgrowth by the
SPOT Advanced program (Media Cybernetics, Sterling Heights,
MI, USA). Microvessel outgrowth was calculated by circling the
extent of microvessel outgrowth at 6 days and subtracting the area
of the aortic ring (29).
DEPLETION OF MACROPHAGES IN VIVO
Liposomes containing either dichloromethylene diphosphonate
(clodronate, a gift from Roche Diagnostics, Germany) or PBS were
prepared as described (30). Mice were injected with clodronate
liposomes (CL-Lip) or PBS liposomes (PBS-Lip) at 100 mg/kg
body weight by intraperitoneal (i.p.) injection twice a week for
up to 4 weeks.
STATISTICAL ANALYSIS
Results showed in figures were presented as mean± SEM with
n representing the frequency of experiments. Student’s unpaired
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t -test was used to evaluate statistical significance with a p value
<0.05 considered significant.
RESULTS
TERATOMA DEVELOPMENT AFTER ESC INJECTION INTO SPINAL CORD
Undifferentiated enhanced gene fluorescent protein (EGFP)–ESCs
were stereotaxically injected into the spinal cord of mice exposed
by a T9–T10 laminectomy. During the first week after ESC injec-
tion, hindlimb function, as reflected by the Basso Mouse Scale
(BMS), was normal. However, the BMS score decreased rapidly
at 10 days after ESC injection and all mice were paralyzed at
day 17 after cell transplantation (Figure 1A) because of rapid
tumor growth (Figure 1B). The mice survived for only 3 weeks
after ESC transplantation (data not shown). Histological exam-
ination revealed that these tumors were teratomas since they
consisted of structures derived from all three embryonic germ
lineages (Figure 1C). While most teratomas are benign, malignant
teratomas do occur. Prognosis is inversely related to stage and his-
tological grade, which is based on the amount of neurepithelium
and immature neural tubes present according to the World Health
Organization (WHO) classification (31). Teratomas of grade 0–1
are classified as benign or low grade, while grade 3 is malignant. We
found that the median teratoma grade in mice was 3.0 (Figure 1D),
indicating that these teratomas in mice were teratocarcinomas.
ESCs STIMULATE MACROPHAGE INFILTRATION
We observed the early infiltration of a large population of
Mac-2+/IBA-1+ macrophages within the teratomas (Figure 1E).
Macrophages can be detected as early as 1 day after ESC injec-
tion, with peak macrophage infiltration occurring after 1 week
(Figures 1E,F). Figure 1F shows the mean density of macrophages
(IBA-1+) recruited at the ESC implantation site at different time
points after ESC injection. Interestingly, there was a significant
reduction in macrophage distribution after 2 weeks. The num-
bers of macrophages at 2 and 3 weeks were significantly less than
those at any earlier time points and the difference between 2 and
3 weeks was no longer significant (Figure 1F). This suggests that
macrophages may play an important role in teratoma initiation. By
contrast, injection of PBS alone in the spinal cord did not induce
macrophage infiltration (data not shown).
TERATOMA DEVELOPMENT IN THE TISSUE OUTSIDE OF SPINAL CORD
To better exclude the effect of neural and glial cells in spinal cord
on teratoma growth and differentiation, an examination of ter-
atomas induced by ESC transplantation in non-neural sites could
support the role of signals produced by macrophages vs. other
tissue types. ESCs were injected into liver and representative ter-
atoma at week 4 is shown in Figure 1G. A large teratoma had
formed in the liver and an enormous number of macrophages was
detected (Figure 1G).
ESC-SECRETED FACTORS ACT AS MACROPHAGE SURVIVAL FACTORS
The ESC-induced macrophage distribution could result from
either increased recruitment of these cells into the teratoma or cell
survival. We first examined the function of ESCs in macrophage
growth. It has been well-documented that M-CSF is a hematopoi-
etic growth factor necessary for monocyte survival, proliferation,
and differentiation (32, 33). L929 conditioned medium is the
source for M-CSF. Mouse ESC-CM (without direct cell–cell con-
tact) and control medium (Con-M, medium to culture ESCs) were
used in the study. Day 7 BMDMs were cultured with DMEM alone,
Con-M and ESC-M and DMEM with M-CSF for 48 h and cell
viability was measured by monitoring metabolic activity of the
cells using MTT assay. Incubation of BMDMs in the presence of
M-CSF and ESC-M caused a significant increase in cell viability
compared to medium without M-CSF (DMEM alone) and Con-
M treatment (Figure 2A). These data suggest that ESC-M can
partially prevent the loss of macrophage viability after M-CSF
withdrawal, although to a lesser extent than did M-CSF. Fur-
thermore, heat-inactivated ESC-M by boiling for 10 min failed
to increase macrophage viability (data not shown).
ESCs PROTECT MACROPHAGES FROMM-CSF WITHDRAWAL-INDUCED
APOPTOSIS IN VITRO
To further evaluate whether the survival effect of ESCs was
due to the inhibition of apoptosis, apoptosis of macrophages
was assessed by surface Annexin V staining using FACS and
caspase-9 activation. When mature BMDMs were cultured with
M-CSF, <10% of cells were Annexin V-positive (Figures 2B,C).
However, when cells were subjected to medium without M-CSF
or Con-M, more than 25% of the cells underwent apoptosis
(Figures 2B,C). Propidium iodide (PI) staining revealed that M-
CSF withdrawal or Con-M treatment for 24 h did not increase
PI-positive macrophages significantly compared to M-CSF or
ESC-M treatment (Figure 2C). Furthermore, Con-M treatment
induced activation of caspase-9, assessed by the appearance of
the cleaved caspase-9 (Figure 2D). Treatment of cells with ESC-
M significantly protected M-CSF withdrawal-induced caspase-9
activation and apoptosis (Figures 2B–D). These results suggest
that the anti-apoptotic effect of ESCs on macrophages resulted in
enhanced cell survival. In order to identify whether ESC-mediated
cell survival is induced directly by mediators in ESC-M or indi-
rectly by stimulating the release of secondary mediators acting
in an autocrine manner, we detected M-CSF and IL-34, the two
most well-documented cytokines that regulate macrophage sur-
vival and differentiation (34). ESCs did not produce M-CSF (data
not shown) but expressed a high level of IL-34 (Figure 2E) and
secreted into the ESC-M (16.034± 4.56 ng/ml, n= 3). BMDM
treated with ESCs did not further increase M-CSF and IL-34
expression (data not shown), suggesting that ESC-induced BMDM
survival is M-CSF-independent and that IL-34 from ESCs may
promote macrophage survival.
ACTIVATION OF PI3K/Akt AND ERK IS NECESSARY FOR ESC-INDUCED
MACROPHAGE SURVIVAL
The PI3K pathway is one of the most potent intracellular mecha-
nisms for promoting cell survival, and PI3K/Akt and extracellular
regulated kinase1/2 (ERK1/2) regulate macrophage survival in
response to M-CSF and IL-34 (35–37). We therefore examined
whether activation of PI3K and ERK1/2 was required for ESC-
mediated macrophage survival. As shown in Figures 3A,B, ESC-M
stimulated phosphorylation of p85 regulatory subunit of PI3K and
ERK1/2 as early as 3 min, and a persistent phosphorylation level
was maintained up to 30 min. ESCs also induced activation of
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FIGURE 1 |Teratoma formation and macrophage infiltration after ESC
injection into spinal cord. (A) ESCs were stereotaxically injected into the
spinal cord in C57BL/6 mice and the function of the hindlimbs was
evaluated by BMS score (n=7, data are represented as mean±SEM). A
score of 0 indicates complete paralysis of the hind limbs and 9 denotes full
mobility. (B) Tumor formation in spinal cord at 3 weeks after GFP–ESC
injection. (C) Histological staining of spinal cord sections at 2 weeks after
ESC injection showing structures derived from three embryonic germ
lineages. (D) Median of teratoma grade in mice (n=6). (E) Representative
micrographs showing macrophage recruitment during teratoma
progression. Macrophages in the sections of spinal cord at 1 day (upper
left), 1 week (upper right), and 3 weeks after ESC transplantation (lower)
were detected by antibodies to IBA-1 (purple) and Mac-2 (red).
(F) Quantification of IBA-1+ macrophages at indicated time points after
ESC transplantation (n=10, *p<0.05, two-sided Wilcoxon test. Data are
represented as mean±SEM). (G) Representative gross morphology of
teratoma in liver (left) and F4/80+ macrophages in teratoma at 4 weeks
after ESC transplantation in liver.
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FIGURE 2 | Embryonic stem cells enhance BMDM survival. (A) Day 7
BMDMs were incubated with DMEM alone in absence of M-CSF, Con-M,
ESC-M, and DMEM in the presence of M-CSF for 48 h. The metabolic activity
of the cells was analyzed by the MTT assay and is presented relative to the
activity of cells treated with DMEM alone (n=3). (B,C) Flow cytometric
analysis of annexin V/propidium iodide (PI) staining of BMDMs treated with
ESC-M, Con-M, DMEM with M-CSF, and DMEM alone for 24 h, respectively
(n=3). (D) Effect of ESCs on caspase-9 activation. BMDMs were treated with
Con-M and ESC-M for 12 and 24 h, respectively and whole cell lysates were
analyzed by Western blotting for caspase-9 activation. (E) IL-34 in BMDMs and
ESCs was detected by Western blot analysis. *p<0.05, two-sided Wilcoxon
test. Data are represented as mean±SEM.
the major downstream kinase Akt of PI3K by phosphorylating
residue Ser473 (Figure 3C). It is interesting to note that ESC-M
also induced NF-κB activation by enhancing IκBα phosphoryla-
tion (Figure 3C). We further determined whether LY-294002 and
PD98059, specific inhibitors of PI3K and ERK1/2, can reverse the
protective role of ESC-M on macrophage survival. Both LY-294002
and PD98059 significantly reduced ESC-mediated macrophage
survival (Figure 3D), suggesting that PI3K and ERK1/2 activation
are required for ESC-mediated macrophage survival. Moreover,
the activation of PI3K and ERK1/2 was inhibited by LY-294002 and
PD98059, respectively, which parallels their effect on macrophage
survival (Figure 3E).
We showed that ESCs produce IL-34 (Figure 2E) and the con-
centration of IL-34 in ESC-M was 16.034± 4.56 ng/ml. We there-
fore examined the ability of mouse recombinant IL-34 to promote
macrophage survival on BMDMs. IL-34 simulated macrophage
survival in a dose-dependent manner (Figure 3F). IL-34 at low
as 10 ng/ml increased macrophage survival. Furthermore, IL-34
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FIGURE 3 | Effect of ESCs on activation of PI3K/Akt, ERK1/2, and
NF-κB pathways. Phosphorylation of p85 (A), p-ERK1/2 (B), and pAkt and
NF-κB (C) in BMDMs treated with Con-M and ESC-M for the indicated
time. (D) Effect of inactivation of PI3K and ERK1/2 in ESC-induced cell
survival. BMDMs were pretreated with PI3K inhibitor LY-294002 (20µM)
and ERK inhibitor PD98059 (10µM) for 30 min and then treated with
Con-M and ESC-M for 48 h. The metabolic activity of the cells was
analyzed by the MTT assay and is presented relative to the activity of cells
treated with Con-M (n=3, *p<0.05, two-sided Wilcoxon test. Data are
represented as mean±SEM). (E) BMDMs were pretreated with PI3K
inhibitor LY-294002 (20µM) and ERK inhibitor PD98059 (10µM) for 30 min
and then treated with Con-M and ESC-M for 30 min. Phosphorylation of
p85 and p-ERK1/2 was detected by Western Blot assay. (F) Effect of IL-34
on macrophage survival. BMDMs were incubated with mouse
recombinant IL-34 at the indicated concentration for 48 h. The metabolic
activity of the cells was analyzed by the MTT assay and is presented
relative to the activity of cells treated with Con-M (n=3, *p<0.05;
**p<0.001, ANOVA, data are represented as mean±SEM).
(G) Phosphorylation of p85 and p-ERK1/2 in BMDMs treated with IL-34
(50 ng/ml) for the indicated time.
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stimulated phosphorylation of ERK1/2 and PI3K in macrophages
to a similar degree, with similar kinetics, compared to ESC-M
treatment (Figure 3G).
ESCs INDUCES TYPICAL SHAPE CHANGE
We next examined how ESCs modulate macrophage function. We
exposed mature BMDMs to interferon γ (IFN-γ), IL-4, ESC-M,
Con-M, and IL-34 for 72 h, respectively. BMDMs present a unique
morphology,depending on the stimulation used. Cells treated with
IL-4, which stimulates M2 activation, adopted a spindle-shape
morphology (Figure 4A). M1 macrophages induced by IFN-γ
had a relatively round shape with large filopodia. Con-M treat-
ment exhibited the typical bipolar, spindle-shaped morphology
of BMDMs. In contrast, ESC-M led to a majority of elongated
fibroblast-like-shaped cells and some of the macrophages showed a
long, single process or bipolar processes (Figure 4A). IL-34 treated
cells demonstrated a wider range of cell length whereas the ESC-M
treated cells displayed a relatively shorter range because the cells
were all approximately the same length (Figure 4A). Quantita-
tive analysis showed that ESC-M-treated macrophages exhibited a
FIGURE 4 | Effect of ESCs on macrophage activation. (A) Representative
phase-contrast photomicrographs of BMDMs (original magnification, ×400).
BMDMs were cultured with M-CSF, IL-4, IFN-γ, IL-34, Con-M, and ESC-M for
72 h. (B) Length of BMDMs incubated with IL-34, Con-M, and ESC-M for 72 h
was measured by ImageJ (n=6, *p<0.05, **p<0.001, two-sided Wilcoxon
test. Data are represented as mean±SEM). (C) Representative
phase-contrast photomicrographs of primary microglial cells incubated with
Con-M and ESC-M for 72 h. Original magnification, ×400.
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significantly higher degree of elongation compared either to Con-
M treated or untreated macrophages (Figure 4B). The average
length of cells treated with IL-34 was longer than that of Con-M
treated cells but shorter than that of ESC-M, suggesting that other
factors produced by ESC-M may have contributed to cell elon-
gation. To further demonstrate that the ESC-induced phenotypic
characteristic was not restricted to BMDMs, we isolated primary
microglial cells from brain. ESC-M also resulted in remarkable
elongation in microglial cells (Figure 4C).
ESCs MAINTAIN MACROPHAGE PHENOTYPE AND FUNCTION
In order to know whether ESC treatment would maintain
macrophage phenotype and function, we analyzed the expres-
sion of macrophage markers such as F4/80 and Mac-2 on cells
treated with ESC-M. BMDMs were treated with Con-M and
ESC-M for 3 days and expression of macrophage markers was con-
firmed by flow cytometry and Western Blot analysis, respectively.
Both Con-M and ESC-M treatment maintained macrophages
expressing a high level of F4/80 (Figure 5A). Mac-2 expression
was enhanced by ESC-M treatment and the expression level was
higher compared with Con-M treatment (Figure 5B). To fur-
ther study, whether ESC-M-treated macrophages were biologi-
cally functional, we incubated BMDMs with apoptotic neutrophils
(PMNs) and latex beads for 30 min. The results showed that ESC-
M-treated BMDMs displayed active functional phagocytosis of
apoptotic cells and latex beads (Figures 5C,D).
ESCs POLARIZE MACROPHAGES INTO UNIQUE M2-LIKE CELLS
In addition to the role of ESCs promoting macrophage infil-
tration and survival, ESCs are able to activate BMDMs and
stew them toward the M2 phenotype (Arginase-1highYM1high)
via activation of STAT3 and STAT6 pathways (24). A recent
study showed that macrophage elongation enhanced the effect
of M2-inducing cytokines and inhibited the effect of M1-
inducing cytokines, suggesting that cell shape has an important
role in modulating macrophage activation (38). We demon-
strated in the present study that the phenotypic characteriza-
tions of ESC-treated macrophages were distinct from classic M2
macrophages induced by IL-4 (Figure 4A). We thus further
evaluated whether ESC-treated macrophages are different from
“alternatively activated” M2 macrophages. Treatment with ESC-
M significantly enhanced arginase-1 (Arg-1) activity in BMDMs
in a time-dependent manner, compared to treatment with Con-
M using a colorimetric assay that detects production of urea
(Figure 5E). The distributions of angiopoietin (Ang) recep-
tor (Tie)-2+ (Tie-2) cells and F4/80+/arginase-1+ macrophages
were detected in the teratoma in vivo (Figure 5F). It has been
shown that M2 express a very low level of TNF-α (39, 40).
However, we showed that macrophages expressed only minimal
TNF-α mRNA in the absence of ESC-M (Figure 5G). Upon co-
culture with ESC-M, TNF-α expression increased significantly in
macrophages (Figure 5G). Furthermore, the amount of TNF-α
secreted into the culture medium was significantly increased in
BMDMs treated with ESC-M compared to the amount present
in supernatants of Con-M-treated macrophages (Figure 5H).
In summary, ESC-macrophages exhibited an Arg-1highTie-
2highTNF-αhigh phenotype, which differs from conventional M2
phenotypes.
ESCs EXERTS ANGIOGENIC ACTIVITY EX VIVO AND IN VIVO
It is widely accepted that tumor growth requires angiogene-
sis. Therefore, fast teratoma growth is supposedly induced by
increased angiogenesis. ESCs were injected into the spinal cord
and images were taken at 3 weeks after cell transplantation. Spinal
cords with teratoma appeared reddish or brownish, suggesting an
increased permeability (Figure 6A). Immunohistochemical analy-
sis of teratoma tissue with anti-CD31 antibody showed a massively
branched intratumoral vascular network at 3 weeks after cell injec-
tion (Figure 6A). This high density of “plexus-like” vascularity
in teratoma may be important for teratoma growth. By con-
trast, injection of PBS alone in the spinal cord did not produce
neovascularization (data not shown).
To better understand the contribution of macrophages to vas-
cular development during teratoma progression, we performed
a ring sprouting ex vivo assay. A 3D-culture of aortic rings in
Matrigel was used to evaluate the outgrowth of linear endothe-
lial structures from the preexisting vessel (41). The aorta ring
assay is thought to more closely mimic multiple stages of in vivo
angiogenesis, including endothelial cell proliferation, migration,
and tube formation. Mouse thoracic aorta was sectioned into 1-
mm rings, and incubated in growth factor-reduced matrigel with
Con-M or ESC-M for 6 days. Sprouting from the rings was pho-
tographed and outgrowth area was quantitated. ESC-M treatment
significantly increased the areas of sprouting (1.81± 0.03 mm2) at
6 days,whereas Con-M-treated ring segments showed little sprout-
ing (Figures 6B,C). Qualitatively, the arborization of endothelial
networks emanating from aortic rings was also more complex in
the rings treated with ESC-M. Together, these data demonstrated
an important role for ESC-mediated angiogenesis in aortic rings
ex vivo.
We showed that ESC-educated macrophages (SEM) exhib-
ited an Arg-1highTie-2highTNF-αhigh phenotype (Figures 5E–H).
In order to know whether TNF-α is responsible for ESC-
enhanced angiogenesis, aortic rings were cultured with TNF-α
at 10 ng/ml for 6 days. A significant increase in angiogenic spout-
ing was observed in aortic rings in response to TNF-α treatment
(Figures 6B,C). Therefore, we consider that TNF-α contributed,
at least partially, to ESC-induced angiogenesis.
It has been shown that macrophages are found around sprout-
ing neovessels and are particularly abundant at the root of the
vascular outgrowth (42). Pharmacologic ablation of macrophages
from aortic explants blocked formation of neovessels in vitro and
reduced aortic ring-induced angiogenesis in vivo (42). We further
determined how crucial macrophages are to the enhanced angio-
genic ability of ESCs. We applied a well-documented approach to
deleted macrophages by treating mice with liposome-encapsulated
clodronate (Cl-Lip) or control liposomes (PBS-Lip) (43). We used
CX3CR1 GFP/− mice, in which one (CX3CR1GFP/+) copy of the
CX3CR1 gene was interrupted by EGFP (44). CX3CR1 is highly
expressed by human and mouse macrophages (45). Intraperi-
toneal injection of mice with Cl-Lip but not control liposomes
(PBS-Lip) resulted in complete depletion of macrophages in the
aortic ring tissue (Figure 6D). Depletion of macrophages by Cl-
Lip led to a markedly reduced angiogenic response to ESC-M
(Figure 6E). However, we cannot rule out the direct effect of
ESC-M on aortic ring sprouting, because Cl-Lip treatment did
not completely inhibit the vascularization (Figure 6E).
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FIGURE 5 | Effect of ESCs on macrophage activation. BMDMs were
incubated with Con-M or ESC-M for 72 h and F4/80 (macrophage marker),
CD45 (hematopoietic marker), and Mac-2 (macrophage marker) were
assessed by flow cytometry (A) and Western Blot (B), respectively.
(C) BMDMs were pretreated with Con-M and ESC-M for 48 h and then
incubated with apoptotic neutrophils for 30 min. The number of macrophages
ingesting apoptotic cells was counted (n=4, data are represented as
mean±SEM). (D) BMDMs pretreated with Con-M and ESC-M ingestion of
latex beads (red, original magnification, ×400). (E) BMDMs were treated with
Con-M and ESC-M for 1 and 2 days and arginase-1 activity was detected by
colorimetric assay (n=3, *p<0.05, two-sided Wilcoxon test. Data are
represented as mean±SEM). (F) Representative confocal images of
immunostaining of sections from mice at 2 weeks after ESC injection
showing positive staining for Tie-2 (red, left) and F4/80 (red, right) Arginase-1
(purple), respectively. (G) TNF-α mRNA in BMDMs treated with Con-M and
ESC-M for 6 and 12 h was detected by real time RT-PCR (n=4, *p<0.05,
two-sided Wilcoxon test. Data are represented as mean±SEM). (H) TNF-α in
the supernatants of BMDMs treated with Con-M and ESC-M for 48 h was
detected by ELISA (n=3, *p<0.05, two-sided Wilcoxon test. Data are
represented as mean±SEM).
TARGETING MACROPHAGES INHIBITS ESC-INDUCED ANGIOGENESIS
AND TERATOMA DEVELOPMENT
A large amount of macrophage infiltration and phenotype of M2-
like macrophages in the teratoma suggested that macrophages
may create a microenvironment for teratoma development.
We depleted macrophage populations from mice to verify
the contribution of macrophages to teratoma growth. We
demonstrated that i.p. injection of Cl-Lip twice a week after ESC
transplantation into liver resulted in near-complete deple-
tion of macrophages in liver and teratoma when assayed at
4 weeks (Figures 7A,B). We also quantified the blood vessel
density by counting the percentage of the area occupied by
cross-section of all blood vessels in an image. We observed
that blood vessel density in teratoma from mice treated with
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FIGURE 6 | Embryonic stem cells induced an angiogenic switch in
macrophages. (A) Representative gross morphology micrograph showing
blood vessel development during teratoma progression (top left) and
immunostaining by endothelial marker CD31 (red) in sections from mice at
3 weeks after ESC injection (top right and bottom). (B) Representative gross
morphology of aortic rings in Matrigel containing Con-M (left panel), ESC-M
(middle panel), or TNF-α at 10 ng/ml (right panel) at day 6. (C) Area of vascular
sprouting at day 6 in Con-M, ESC-M, and TNF-α was measured by ImageJ
(n=6, *p<0.05, two-sided Wilcoxon test. Data are represented as
mean±SEM). (D) Representative gross morphology of aortic ring from
CX3CR1GFP/+ mice treated with PBS-Lip (left) and CL-Lip for 4 weeks (right).
(E) Mice were treated with PBS-Lip (left) and CL-Lip (right) for 4 weeks and
aortic rings were cultured in Matrigel containing ESC-M for 6 days.
Representative gross morphology of aortic ring sprouting was taken.
Cl-Lip was significantly lower than that of control treatment
(Figure 7C). Blood vessels were significantly smaller in Cl-Lip-
treated teratoma compared to control treatment (Figure 7C).
Depletion of macrophages did not affect the pluripotency of ESCs,
as all three germ layers can be observed in macrophage-deleted
teratoma (Figure 7D). Teratomas from mice treated with
PBS-Lip appeared much darker and were filled with blood,
indicating that functional vasculature had formed via angiogene-
sis (Figure 7E). In contrast, tumor tissue from mice treated with
Cl-Lip was transparent (Figure 7E). Subsequently, ablation of
macrophages significantly inhibited teratoma growth, with a mean
tumor size of 83.13± 60.81 mm3 in Cl-Lip group vs. 2502.75±
1410.02 mm3 in mice treated with PBS-Lip (n= 5, p< 0.05,
Figure 7F).
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FIGURE 7 | Depletion of macrophages inhibiting angiogenesis and
teratoma growth. (A) Cl-Lip was administrated i.p. at the day for ESC
injection and twice a week for 4 weeks. PBS-Lip was used as control.
Liver tissues were stained with F4/80. Note that Cl-Lip treatment
completely depleted F4/80+ macrophages in liver harvested from the
Cl-Lip-treated group (left) and control group (treated with PBS-Lip) at
4 weeks after ESC transplantation. Quantification of F4/80+
macrophages (B), density of blood vessels stained for CD31 [(C), left],
size of blood vessels [(C), right], HE staining (D), and representative
images of teratomas (E) in teratomas from Cl-Lip- or PBS-Lip-treated
mice at 4 weeks after ESC transplantation. (F) Average teratoma size at
4 weeks after ESC transplantation in the Cl-Lip and PBS-Lip treated
groups. *p<0.05, **p<0.001, n=5, two-sided Wilcoxon test. Data
are represented as mean±SEM.
DISCUSSION
In this study, we demonstrated for the first time that BMDMs
can be guided by ESCs to migrate to the site of ESC implantation
while soluble factor(s) produced by ESCs polarize macrophages
into a novel Arg-1highTie-2highTNF-αhigh phenotype. Further-
more, ESCs can prevent BMDM apoptosis induced by M-CSF-
withdrawal through PI3K/Akt and ERK1/2 activation. We demon-
strated that these ESC-educated macrophages (SEM) exhibit an
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elongated morphology and produce high level of TNF-α, which
participates in angiogenesis and contributes to teratoma progres-
sion. Depletion of macrophages completely inhibits ESC-induced
angiogenesis and teratoma development. These studies provide
a novel rationale for the control of teratoma development by
targeting macrophage growth or activation.
Macrophage colony-stimulating factor is known to regulate
monocyte/macrophage survival (32, 33). PI3K/Akt and ERK or
MARK are the major signaling pathways triggered by M-CSF stim-
ulation (35, 46, 47). We showed that ESCs promote the survival
of cultured BMDMs after M-CSF withdrawal, and that activa-
tion of both PI3K/Akt and ERK1/2 MAP kinase are required for
the survival effect of ESCs, which is similar to that activated by
M-CSF. ESC-maintained macrophage survival and function was
independent of M-CSF, because M-CSF was detectable neither in
ESC-M nor in ESC-M-treated macrophages (24). In the present
study, we studied whether other factors are involved as autocrine
or paracrine effectors to induce macrophage survival. For example,
GM-CSF and IL-4 are known to regulate monocyte/macrophage
survival (48). Our results ruled out the requirement for GM-CSF
and IL-4, as these cytokines were undetectable in ESC-M (24).
Recent studies reported that IL-34 is an alternative ligand for M-
CSF receptor (CSF-1R) (34, 49). IL-34 binds specifically to human
and mouse myeloid cells, induces ERK1/2 activation, and supports
macrophage proliferation and differentiation (34). We showed that
IL-34 is highly expressed by ESCs. IL-34 promotes macrophage
survival and activates ERK and PI3K pathways. Although IL-34
also results in cell elongation, its effect is not as strong as that
of ESC-M. It is possible that other soluble factors produced by
ESCs play a role in cell shape change. It has been reported recently
that IL-34-activated macrophages exhibit an IL-10high IL-12low
M2 profile in response to LPS stimulation (50). Therefore, it is
likely that IL-34 produced by ESCs play a pivotal role in ESC-
induced macrophage survival and M2 polarization. More studies
are needed to investigate whether IL-34 secretion and M2-like
polarization of macrophages are general features of ESCs.
It is interesting to note that a large number of macrophages
exist in the early stage of teratoma development and the number
of macrophages rapidly declines at 2 weeks after ESC injection.
We reasoned that ESCs have ability to regulate macrophage sur-
vival and activation. The inhibition of macrophage apoptosis by
ESCs at an early stage may favor teratoma initiation and develop-
ment. However, the effect of ESCs on macrophage may be reduced
once ESCs are differentiated into its three germ layer structures.
It will be important to determine whether fully differentiated tis-
sues lose the ability to maintain macrophage function or have the
capacity to inhibit macrophage survival. Beside IL-34, the factors
produced by ESCs that promote macrophage growth and pro-
gram M2-like phenotype remain unknown. It is possible that the
function/phenotypes of macrophages are regulated by coordinated
action of different classes of molecules secreted by ESCs. How-
ever, more detailed studies will be necessary to determine whether
additional molecules either alone or in combination contribute to
macrophage survival. The identification of these factors appears
crucial in the development of strategies to prevent and/or reverse
macrophage phenotype and thereby increase the safety of stem cell
applications in clinical settings.
Beside mediation of macrophage survival, ESCs are able to
regulate macrophage activation. It is well-documented that M1
macrophages express high levels of nitric oxide (NO), reactive
oxygen species (ROS), and TNF-α, contributing to tissue inflam-
mation and damage. In contrast, M2 macrophages produce anti-
inflammatory factors and have a reduced capacity to produce
pro-inflammatory molecules, thereby contributing to wound heal-
ing and tissue remodeling, as well as tumor progression (51–53).
Tumor microenvironment educates macrophages to perform sup-
portive roles that initiate and promote tumor progression (28).
Tumor-associated macrophages (TAMs) have many properties of
M2 phenotype such as impaired expression of IL-12 and TNF-
α, and up-regulated levels of M2 markers including Arg-1 and
YM1 (54–58). However, TAMs from several tumor models also
exhibit typical M1 cytokines such as TNF-α and IL-1β (59). We
previously showed that ESC-treated macrophages express higher
levels of M2 markers such as PPAR-γ, Arg-1, YM1, as well as
M2 cytokines including VEGF, MMP9, and MCP-1 (24), sug-
gesting that ESCs induced the M2-like phenotype. In the present
study, we demonstrated that ESCs not only increased Arg-1 and
Tie-2+ expression but also triggered TNF-α expression, imply-
ing that ESC-educated macrophages are different from classic
M2 macrophages and resemble more TAMs. ESCs–macrophages
not only exhibited M2 characteristics (expression of M2 mark-
ers and STAT3/6 activation) but also acquired properties of M1
macrophages (activation of NF-κB) and TAMs (high levels of Tie-
2 and TNF-α), exhibiting enhanced neovasculation in an in vitro
and ex vivo angiogenesis assay. Another point of interest is that
ESCs also activate the NF-κB pathway. Defective NF-κB activation
within macrophages leads to the development of an M2 activa-
tion. Although ESCs are not oncogenically transformed, they have
potent ability to regulate macrophage function and induce the
unique Arg-1highTie-2highTNF-αhigh phenotype. Tie-2-expressing
monocytes/macrophages (TEM) share some characteristics with
M2 macrophages and are highly pro-angiogenic cells critical
for tumor vascularization (59, 60). Tie-2 expression can be up-
regulated by TNF-α (61). Specific depletion of TEM or conditional
Tie2 knockdown inhibits tumor angiogenesis. (62–64). Within the
ESC implantation site, the presence of Tie-2+ macrophages and
TNF-α secreted by ESC-macrophages stimulates angiogenesis and
supports teratoma growth. Several angiogenic molecules may be
linked to ESC-induced angiogenesis. We previously showed that
ESCs increased macrophage MIF, MMP9, VEGF, and MCP-1. MIF
secretion is tightly regulated by TNF-α (65, 66) and MIF can also
increase TNF-α expression (67, 68). Therefore, TNF-α may be
the key factor in ESC-induced angiogenesis. Anti-TNF-α agents
such as infliximab (IFX), etanercept (ETA), adalimumab (ADA),
golimumab (GLM), and certolizumab pegol (CZP) have been
widely used for the treatment of a variety of chronic inflamma-
tory diseases. Thus targeting TNF-α by administration of TNF-α
antagonists may be a promising option to suppress teratoma
angiogenesis. However, side effects such as increasing frequency
of infection and promoting tumor growth by induction of T cell
apoptosis make anti-TNF-α treatment a difficult balance. Admin-
istration of CZP can minimize this side effect since it does not
induce T cell apoptosis but remains an efficacious treatment for
inflammatory diseases because of the lack of an Fc region (69).
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Embryonic stem cells can attract macrophages, induce M2 acti-
vation, and promote macrophage survival, and consequently, inhi-
bition of any of these three functions could potentially offer a ther-
apeutic solution to prevent teratoma development. A few strate-
gies are developed to target macrophages: inhibiting macrophage
migration, suppressing macrophage survival, promoting M1 acti-
vation, and blocking M2 polarization (70). Our data suggested
that IL-34 maybe important to maintain macrophage survival
via activation of PI3K and ERK1/2. Therefore, targeting IL-34
and the PI3K/ERK pathways could decrease macrophage number
effectively and alter the microenvironment involved in teratoma
angiogenesis and development. Because IL-34 was recently discov-
ered (34), no antagonists are currently available to inhibit IL-34
activity. Thus, in turn, the antagonists of IL-34 receptor (CSF-1R)
can be applied to block IL-34 binding to its receptor. Anti-CSF-
1R treatment to inhibit tumor growth in vitro and in vivo has
been well-documented (71, 72). Similar strategies can be applied
to target macrophages in teratoma models. In addition, com-
bined targeting of the ERK1/2 and PI3K pathways in teratoma
may be a potential therapeutic strategy. Numerous small mole-
cule inhibitors of specific PI3K and ERK1/2 pathways have been
developed to exhibit promising anti-tumor activity in vitro and
in vivo (73). For example, therapy with a dual PI3K (ZSTK474)
and MEK inhibitor (CI-1040) combination is more effective than
either inhibitor alone in cancer treatment (74). Combination of
the PI3K inhibitor GDC-094 and the MEK inhibitor PD 0325901
induced marked tumor growth inhibition in vivo (75). Further
study is required to demonstrate whether the dual PI3K and ERK
inhibition have anti-teratoma activity in vivo, either through direct
inhibition of macrophage survival, or ESC growth because PI3K
is implicated in regulation of ESC proliferation (76).
Specifically, targeting M2 or TAM-like cells remains challeng-
ing. It has been shown that pharmacological skewing of TAM
polarization from an M2 macrophage phenotype to a full M1
macrophage phenotype sustains anti-tumor immunity (57). It
is possible to re-polarize TAMs. The recent report showed that
M2pep, a peptide, can preferentially binds to M2 macrophages
with low affinity for other leukocytes. Systemical administration
of an M2pep fusion peptide with a proapoptotic peptide specifi-
cally reduced M2-like macrophages (77). A combination of CpG
oligodeoxynucleotides and an IL-10 receptor-specific antibody
switched TAMs from an M2 to an M1 type and triggered an innate
response that was able to cure the majority of mice bearing large
tumors (78).
One therapeutic option is to target STAT3. Numerous stud-
ies demonstrated that constitutive activation of STAT3 promotes
initiation and development of tumors by inducing cell prolifer-
ation, angiogenesis, and metastasis in a wide variety of tumors
(79). Furthermore, STAT3 is a critical mediator of LIF-induced
signaling pathways that regulate ES cell self-renewal and prolifer-
ation (80). STAT3 also contributes to M2 macrophage activation.
Therefore, STAT3 could be an attractive target to control teratoma
development by direct effects on ESC growth and macrophage M2-
like activation. Numerous strategies to suppress STAT3 activation
have been developed such as anti-sense oligonucleotide target-
ing STAT3, synthetic drugs, small molecules, and gene therapy
techniques (79).
In conclusion, our present findings show an important link
between ESC-induced macrophage infiltration, growth and acti-
vation, initiation of angiogenesis, and teratoma development.
ESCs induce BMDM accumulation and stew novel pro-angiogenic
phenotype and thus accelerate teratoma development. A better
understanding of the regulation and function of macrophages in
the tumorigenicity of ESCs may yield useful therapies for the safe
transplantation of ESCs. Targeting of the host microenvironment
of the transplantation site such as modulating macrophage phe-
notype and function rather than ESCs directly could be a more
efficient approach for suppressing angiogenesis and teratoma
progression without affecting the pluripotency of ESCs.
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